About
our project
WHY EVAMOBS
Pandemic preparedness
With globalization and climate change, the world is at higher risk of new viral outbreaks. Preventing new pandemics requires us to be prepared and act fast, before a new virus causes a new pandemic.
This is why EvaMobs is working on an innovative tool for the rapid and efficient development of new antivirals. This way, we can develop new antivirals fast, preventing a large viral outbreak.
A monobody (in pink) tightly bound to the
SARS-COV-2 receptor binding domain (in blue). Monobodies are one of the protein-based antiviral approaches investigated by EvaMobs.
MONOBODIES
A novel platform to develop antivirals
EvaMobs is taking a new approach in antiviral development, by creating a platform to design small proteins, such as monobodies (Mobs), miniproteins, or nanobodies, against different viruses.
The antiviral proteins can be tailored to have a high affinity for any type of virus. In other words, by making specific changes to the framework of the proteins, this technology can be used to easily generate specific molecules that can “attack” and inactivate a particular virus.
Existing antiviral methods mostly use monoclonal antibodies (mAbs). Mobs for example are an alternative to this. Mobs are smaller than mAbs, allowing for a lower dosage to use. In addition, Mobs are derived from a human protein, making them less prone to evoke an immune response.
To ensure success across diverse epitopes, our scaffold portfolio also includes miniproteins, which are very small, highly stable binders, and nanobodies, the minimal antigen-binding fragments of the heavy-chain-only antibodies naturally produced by camelids.
EvaMobs will combine artificial intelligence and structure-based computational design to develop a framework that can easily discover, produce and validate the most effective Mob, miniprotein or nanobody as new antivirals.
ABOUT EVAMOBS
Our research steps
Discover new
antiviral candidates
With a computational framework, millions of computer-designed antiviral proteins will be discovered, and characterised.
Production of
specific antiviral
proteins
A narrowed down selection of discovered antivirals will be produced.
Preclinical
validation
The antiviral proteins will undergo testing of the safety, efficacy and the dosage in preclinical models.
Phase 1 clinical
validation
The most promising antiviral protein will be tested for safe use in humans.
Discovery of new Mobs
With a computational framework, millions of computer-designed Mobs will be discovered, and characterised.
![]()
Production of specific Mobs
A narrowed down selection of discovered Mobs will be produced.
![]()
Preclinical validation
The Mobs will undergo testing of the safety, efficacy and the dosage in preclinical models.
![]()
Phase 1 clinical validation
The most promising Mob will be tested for safe use in humans.
![]()
Discover antiviral candidates
With a computational framework, millions of computer-designed antiviral proteins will be discovered, and characterised.
![]()
Production of
specific antiviral proteins
A narrowed down selection of discovered antivirals will be produced.
![]()
Preclinical validation
The antiviral proteins will undergo testing of the safety, efficacy and the dosage in preclinical models.
![]()
Phase 1
clinical validation
The most promising antiviral protein will be tested for safe use in humans.
OUR WORK
Work packages
EvaMobs has been divided into 6 work packages (WP), as described below:
- WP1 – Discovery of new antiviral proteins
- WP2 – Production of specific antiviral proteins
- WP3 – Preclinical validation
- WP4 – Phase 1 clinical validation
- WP5 – Communication and Dissemination
- WP6 – Project Management
WP1 – Discovery of new antiviral proteins
In this work package, EvaMobs will leverage computational methods, including AI- and physics-based tools for developing a discovery framework capable of creating small proteins, such as monobodies (Mobs), miniproteins or nanobodies, tailored to effectively bind to a neutralizable target on the surface of a virus. This framework will be tested for 4 test-case viruses: SARS-CoV-2, Respiratory syncytial virus (one of the most common cold viruses), Influenza A Virus (flu), and Zika Virus to showcase that it can be adapted to different viruses, representing a broad-spectrum antiviral strategy.
This WP will generate antiviral protein sequences and predict the structures of these proteins in complex with the target that will be evaluated in WP2 and WP3, which in turn will provide experimental data that will allow the refinement of computational methods and increase its success rate. By implementing an efficient computational framework we will be able to drastically reduce the resources and time required for developing antiviral proteins tailored for a given virus, even when it emerges unexpectedly.
Partners involved:

![]()
WP2 – Production of specific antiviral proteins
EvaMobs will implement a high-throughput pipeline to produce and evaluate Mobs, miniproteins and nanobodies, testing their production yield, stability in solution (a pre-requisite for formulation as a biopharmaceutical), and binding activity.
The antiviral proteins will then be ranked based on their performance, and the most stable and high-affinity ones will be optimized for production. Promising candidates will then be formulated for preclinical and clinical trials. The final selected candidate will be produced following good manufacturing practices (GMP) conditions for phase I clinical trials.
Partners involved:


WP3 – Preclinical validation
In this work package, EvaMobs will determine the antiviral activity of at least 25 antivirals against SARS-CoV-2, Respiratory syncytial virus, Influenza A Virus, and Zika Virus.
After initial assessment in cells, the most promising antiviral candidates will be evaluated for antiviral activity in preclinical models for virus replication, clinical outcomes, and immune responses. Altogether, these studies will provide information on safety and effective dosage levels to create a thorough preclinical report on a selected set of antiviral Mobs, miniproteins or nanobodies.
Partners involved:

![]()

![]()
![]()
WP4 – Phase 1 clinical validation
In this work package, a Phase I clinical trial will be developed and conducted to evaluate the safety of a lead antiviral protein in humans. Preparation for the clinical trial will be done according to ICH guidelines followed by submission to regulatory authorities.
After approval, the trial will be conducted and data will be collected and analysed to generate a comprehensive Clinical Study Report (CSR) with the final assessment of the antiviral.
Partners involved:
![]()
WP5 – Communication and Dissemination
In this work package, plans for communication, dissemination and future exploitation of project results will be established to ensure the project’s visibility and maximize result uptake. This will include identifying target audiences to ensure effective communication and promote education on antiviral proteins and pandemic preparedness. EvaMobs will engage with the general public, as well as the scientific community, industry and regulatory and health authorities.
Strategies for exploitation, IP protection, networking with SMEs for future clinical trials, and stakeholder engagement will also be outlined.
Partners involved:
![]()
For exploitation:

WP6 – Project management
This work package focuses on the management of EvaMobs to ensure efficient decision-making, communication, and successful project implementation. It will include overseeing project progress, financial, administrative, and legal management, and ensure communication between partners and the European Commission.
The management structure of EvaMobs includes several committees that oversee scientific and technical work, management and communication ensuring the effective exploitation and dissemination of project results. Furthermore, the implementation of a FAIR Data Management Plan will facilitate data sharing in compliance with EU legislation on ethics and data protection.
Partners involved:

- WP1 – Discovery of new antiviral proteins
- WP2 – Production of specific antiviral proteins
- WP3 – Preclinical validation
- WP4 – Phase 1 clinical validation
-
WP5 – Communication and
Dissemination - WP6 – Project Management
WP1 – Discovery of new antiviral proteins
In this work package, EvaMobs will leverage computational methods, including AI- and physics-based tools for developing a discovery framework capable of creating small proteins, such as monobodies (Mobs), miniproteins or nanobodies, tailored to effectively bind to a neutralizable target on the surface of a virus. This framework will be tested for 4 test-case viruses: SARS-CoV-2, Respiratory syncytial virus (one of the most common cold viruses), Influenza A Virus (flu), and Zika Virus to showcase that it can be adapted to different viruses, representing a broad-spectrum antiviral strategy.
This WP will generate antiviral protein sequences and predict the structures of these proteins in complex with the target that will be evaluated in WP2 and WP3, which in turn will provide experimental data that will allow the refinement of computational methods and increase its success rate. By implementing an efficient computational framework we will be able to drastically reduce the resources and time required for developing antiviral proteins tailored for a given virus, even when it emerges unexpectedly.
Partners involved:

![]()
WP2 – Production of specific antiviral proteins
EvaMobs will implement a high-throughput pipeline to produce and evaluate Mobs, miniproteins and nanobodies, testing their production yield, stability in solution (a pre-requisite for formulation as a biopharmaceutical), and binding activity.
The antiviral proteins will then be ranked based on their performance, and the most stable and high-affinity ones will be optimized for production. Promising candidates will then be formulated for preclinical and clinical trials. The final selected candidate will be produced following good manufacturing practices (GMP) conditions for phase I clinical trials.
Partners involved:


WP3 – Preclinical validation
In this work package, EvaMobs will determine the antiviral activity of at least 25 antivirals against SARS-CoV-2, Respiratory syncytial virus, Influenza A Virus, and Zika Virus.
After initial assessment in cells, the most promising antiviral candidates will be evaluated for antiviral activity in preclinical models for virus replication, clinical outcomes, and immune responses. Altogether, these studies will provide information on safety and effective dosage levels to create a thorough preclinical report on a selected set of antiviral Mobs, miniproteins or nanobodies.
Partners involved:

![]()

![]()
![]()
WP4 – Phase 1 Clinical Validation
In this work package, a Phase I clinical trial will be developed and conducted to evaluate the safety of a lead antiviral protein in humans. Preparation for the clinical trial will be done according to ICH guidelines followed by submission to regulatory authorities.
After approval, the trial will be conducted and data will be collected and analysed to generate a comprehensive Clinical Study Report (CSR) with the final assessment of the antiviral.
Partners involved:
![]()
WP5 – Communication and Dissemination
In this work package, plans for communication, dissemination and future exploitation of project results will be established to ensure the project’s visibility and maximize result uptake. This will include identifying target audiences to ensure effective communication and promote education on antiviral proteins and pandemic preparedness. EvaMobs will engage with the general public, as well as the scientific community, industry and regulatory and health authorities.
Strategies for exploitation, IP protection, networking with SMEs for future clinical trials, and stakeholder engagement will also be outlined.
Partners involved:
![]()
For exploitation:
WP6 – Project management
This work package focuses on the management of EvaMobs to ensure efficient decision-making, communication, and successful project implementation. It will include overseeing project progress, financial, administrative, and legal management, and ensure communication between partners and the European Commission.
The management structure of EvaMobs includes several committees that oversee scientific and technical work, management and communication ensuring the effective exploitation and dissemination of project results. Furthermore, the implementation of a FAIR Data Management Plan will facilitate data sharing in compliance with EU legislation on ethics and data protection.
Partners involved:
